| Ytd | -57.82% | |
| 1y | -84.66% |
| Open | 6.82 | Prev Close | 6.89 | Low | 6.80 | High | 6.98 | Mkt Cap | 45.45M |
| Vol | 8.55K | Avg Vol | 17.53K | EPS | -6.29 | P/E | N/A | Forward P/E | N/A |
| Beta | 0.18 | Short Ratio | 0.09 | Inst. Own | 3.82% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-13 | 50-d Avg | 6.29 | 200-d Avg | 11.04 | 1yr Est | 4.20 |
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced th
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 159.6% to $7.68 during Monday&
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced the
Tevogen Bio Holdings (NASDAQ:TVGN) reported quarterly losses of $(1.61) per share which beat the ana
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced tha
Potential transaction expected to add $20M+ in revenue and support double-digit growth, further stre
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) received written no
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced per
U.S. stock futures lower, with Dow futures down over 1%. BETA Technologies (NYSE: BETA) fell in pre-
Leadership Designations:Digital Health: Arpita Patel and Wojtek StobinskiGenerics: Sadiq Khan and Da
Tevogen stock swings after Apozeal acquisition talks and a 50-for-1 reverse split as TVGN trades nea
Dow Jones falls 500 points on Friday, Marvell Technology shares jump 18.4%, other stocks recording g
If consummated, the potential acquisition of Apozeal could provide Tevogen with an established gener
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced tha
D. Boral Capital analyst Jason Kolbert maintains Tevogen Bio Holdings (NASDAQ:TVGN) with a Buy an
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced tha
Tevogen ("Tevogen Bio Holdings Inc.") (NASDAQ:TVGN) today announced that it has entered into
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced tha
Jan. 12, 2026, San Francisco. Issued from the J.P. Morgan Healthcare ConferenceWARREN, N.J., Jan. 12
Pipeline Expansion Across Multiple Indications:Building on its SARS-CoV-2 proof-of-concept clinical
D. Boral Capital analyst Jason Kolbert maintains Tevogen Bio Holdings (NASDAQ:TVGN) with a Buy an
This milestone expands patient eligibility through multi-HLA targetingBuilds on completed TVGN 489 t
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today issued a sta
Company intends to collaborate with government initiatives, Long COVID patient organizations, and ma
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ: TVGN), today announced s
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today highlights e
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ: TVGN), today shared asse
The risk adjusted Net Present Value (rNPV) for TVGN 930 is estimated to exceed ~$250 million in the
D. Boral Capital analyst Jason Kolbert maintains Tevogen Bio Holdings (NASDAQ:TVGN) with a Buy an
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today highlighted
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announced an
Includes $36 million line of credit and potential $14 million private placementWARREN, N.J., Aug. 19
D. Boral Capital analyst Jason Kolbert maintains Tevogen Bio Holdings (NASDAQ:TVGN) with a Buy an
Tevogen Bio Holdings Inc. ("Tevogen" or the "Company") (NASDAQ:TVGN), today issued t
Treatment of a subgroup of patients with post-acute sequelae of SARS-CoV-2.Forecast adds to Tevogen
Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (NASDAQ:TVGN), a clinical-sta
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announced an
D. Boral Capital analyst Jason Kolbert maintains Tevogen Bio Holdings (NASDAQ:TVGN) with a Buy an
WARREN, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "
D. Boral Capital analyst Jason Kolbert maintains Tevogen Bio Holdings (NASDAQ:TVGN) with a Buy an
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today released a l
Funds will support advancement of Tevogen.AI, the Company's artificial intelligence–driven drug